Daniel Muldoon

9PUBLICATIONS
135CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsCancer geneticsRespiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 26, 2026
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.

Wungki Park, Catherine A O'Connor, Joanne F Chou

|Mar 25, 2026
A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.

Maria M Rubinstein, Jennifer Y Ge, Qin Zhou

|Jan 28, 2026
Genomic Enrichment and Functional Impact of TP53 and CYLD Alterations in Recurrent and Metastatic HPV-Associated Head and Neck Cancer.

Manu Prasad, Alex T Cheng, Marcel Mayer

|Sep 15, 2025
Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial.

Wungki Park, Catherine O'Connor, Joanne Chou

|Jun 02, 2025
Longitudinal and multisite sampling reveals mutational and copy number evolution in tumors during metastatic dissemination.

Karena Zhao, Joris Vos, Stanley Lam

|Jan 03, 2025
Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival.

Anna M Varghese, Maria A Perry, Joanne F Chou

Pageof 2

Frequent Collaborators

8 joint publications

Chaitanya Bandlamudi

5 joint publications

Michael F Berger

3 joint publications

Nadeem Riaz

3 joint publications

Maria Perry